BioVie Inc. (BIVI)

NCM – Real Time Price. Currency in USD

1.72

+0.45 (35.18%)

Market open: Aug 12, 2026, 12:43 PM EDT

1.23

-0.04 (-3.15%)

Previous after-hours: Aug 11, 2026, 7:58 PM EDT

07.08.2026

Parkinson's drug developers are betting big on inflammation

For years, the hunt for a Parkinson's disease-modifying drug came down to one protein: alpha-synuclein. Clear it out, the thinking went, and you slow the disease.

06.08.2026

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage Parkinson's disease, with patients showing improvements in blood-based inflammatory markers and a range of clinical outcomes compared with placebo. The SUNRISE-PD trial was a multicenter, randomized, double-blind, placebo-controlled study in patients with early-stage Parkinson's disease who had not previously been treated with carbidopa/levodopa.

06.08.2026

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS 1 Parts I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures. Bezisterim treatment appeared to have a beneficial impact on plasma biomarkers of neurodegeneration and reduced biomarkers of both neuro- and systemic-inflammation.

Videos

No Data

There is no data to display

Press releases

06.08.2026

BioVie Inc. (BIVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioVie Inc. (BIVI)

Parkinson's drug developers are betting big on inflammation

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Videos

No Data

Press releases

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Parkinson's drug developers are betting big on inflammation

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Videos

No Data

Press releases

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Search stocks

BioVie Inc. (BIVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioVie Inc. (BIVI)

Parkinson's drug developers are betting big on inflammation

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Videos

No Data

Press releases

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Parkinson's drug developers are betting big on inflammation

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

Videos

No Data

Press releases

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease